CL2021001602A1 - Formas polimórficas novedosas de un inhibidor de tgfß - Google Patents

Formas polimórficas novedosas de un inhibidor de tgfß

Info

Publication number
CL2021001602A1
CL2021001602A1 CL2021001602A CL2021001602A CL2021001602A1 CL 2021001602 A1 CL2021001602 A1 CL 2021001602A1 CL 2021001602 A CL2021001602 A CL 2021001602A CL 2021001602 A CL2021001602 A CL 2021001602A CL 2021001602 A1 CL2021001602 A1 CL 2021001602A1
Authority
CL
Chile
Prior art keywords
polymorphic forms
tgfß
inhibitor
novel polymorphic
relates
Prior art date
Application number
CL2021001602A
Other languages
English (en)
Inventor
Anand Venkataramana Sistla
Iain David Roy
Andrew Robbins
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CL2021001602A1 publication Critical patent/CL2021001602A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/18—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a formas amorfas y polimórficas cristalinas novedosas de 4-(2-(5-cloro-2-fluorofenil)-5-isopropilpiridin-4-ilamino)-N-(1,3-dihidroxipropan-2-il)nicotinamida y a métodos para su preparación; y la invención también se refiere a composiciones farmacéuticas que contienen al menos una forma polimórfica y al uso terapéutico o profiláctico de tales composiciones y formas polimórficas.
CL2021001602A 2018-12-20 2021-06-17 Formas polimórficas novedosas de un inhibidor de tgfß CL2021001602A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782411P 2018-12-20 2018-12-20
US201962930170P 2019-11-04 2019-11-04

Publications (1)

Publication Number Publication Date
CL2021001602A1 true CL2021001602A1 (es) 2022-01-21

Family

ID=69159846

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001602A CL2021001602A1 (es) 2018-12-20 2021-06-17 Formas polimórficas novedosas de un inhibidor de tgfß

Country Status (22)

Country Link
US (1) US20200199104A1 (es)
EP (1) EP3898591A1 (es)
JP (1) JP2022513925A (es)
KR (1) KR20210104808A (es)
CN (1) CN113272279A (es)
AU (1) AU2019404250B2 (es)
BR (1) BR112021010577A2 (es)
CA (1) CA3123829A1 (es)
CL (1) CL2021001602A1 (es)
CO (1) CO2021007875A2 (es)
CR (1) CR20210334A (es)
EC (1) ECSP21044734A (es)
IL (1) IL284226A (es)
MA (1) MA54526A (es)
MX (1) MX2021007251A (es)
PE (1) PE20211756A1 (es)
PH (1) PH12021551459A1 (es)
PY (1) PY19106776A (es)
SG (1) SG11202105763SA (es)
TW (1) TWI743631B (es)
UY (1) UY38517A (es)
WO (1) WO2020128850A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829493B2 (en) 2019-04-12 2020-11-10 Blueprint Medicines Corporation Compositions and methods for treating KIT- and PDGFRA-mediated diseases
WO2022130206A1 (en) * 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
CN112843058A (zh) * 2021-01-27 2021-05-28 复旦大学附属华山医院 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用
WO2022229846A1 (en) * 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
CN120114413B (zh) * 2025-03-17 2025-11-21 珠海市人民医院 一种pH-超声双响应白蛋白纳米药物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201384T1 (hr) * 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe

Also Published As

Publication number Publication date
CO2021007875A2 (es) 2021-07-19
MX2021007251A (es) 2021-07-15
CA3123829A1 (en) 2020-06-25
UY38517A (es) 2020-07-31
AU2019404250B2 (en) 2022-12-22
TWI743631B (zh) 2021-10-21
US20200199104A1 (en) 2020-06-25
KR20210104808A (ko) 2021-08-25
EP3898591A1 (en) 2021-10-27
BR112021010577A2 (pt) 2021-08-24
ECSP21044734A (es) 2021-07-30
AU2019404250A1 (en) 2021-07-01
PE20211756A1 (es) 2021-09-07
SG11202105763SA (en) 2021-07-29
WO2020128850A1 (en) 2020-06-25
IL284226A (en) 2021-08-31
CN113272279A (zh) 2021-08-17
PY19106776A (es) 2021-06-16
PH12021551459A1 (en) 2022-04-11
CR20210334A (es) 2021-07-14
MA54526A (fr) 2022-03-30
TW202039462A (zh) 2020-11-01
JP2022513925A (ja) 2022-02-09

Similar Documents

Publication Publication Date Title
CL2021001602A1 (es) Formas polimórficas novedosas de un inhibidor de tgfß
CL2021003022A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar enfermedad de huntington (div. sol. 202003378).
CL2019003610A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477).
JOP20250289A1 (ar) صور بلورية جديدة
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
MX374012B (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
AU2019333310A8 (en) Salts and crystal forms of GABAA positive allosteric modulator
BR112015007937A2 (pt) formas cristalinas de um inibidor de fator xia
NI201500139A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales
MX2019012967A (es) Cristal de base libre de derivados benzofurano y metodo de preparacion.
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
MX2021015853A (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida.
EA202090119A1 (ru) Аморфные и кристаллические формы ido-ингибиторов
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
MX2020005332A (es) Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion.
AR082418A1 (es) Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
BR112022002772A2 (pt) Formas cristalinas de análogos de quinolina e sais dos mesmos, composições e seus métodos para uso
CL2017002180A1 (es) Formas cristalinas de un compuesto de pirrolopiridina
MX2020009412A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
PH12020500385A1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof